|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | From chemotherapy to targeted therapy in adjuvant treatment for stageⅢ colon cancer显示文摘 | de Gramont A de Gramont A Chibaudel B | 2011 | Semin Oncol2011，38，4： | 1 |
| 2 | Finalresuhs of OPTIMOX2, a large randomized phase ]I study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study 显示文摘 | Maindrault-Goebel F Lledo G Chibaudel B | 2007 | J Clin Oncol2007，25，18： | 1 |
| 3 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study 显示文摘 | Chibaudel B Maindrauh-Goebel F Lledo G | 2009 | J Clin Oncol2009，27，34： | 1 |
| 4 | Can chemotherapy be discontinued in unresectable Metastatic colorectal cancer? The GERCOR OPTIMOX2 study显示文摘 | Chibaudel B Maindrault-Goebel F Lledo G | | 0，，34： | 1 |
| 5 | Final results of OPTIMOX2, a large randomized phase Ⅱ study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC) : a GERCOR study显示文摘 | Maindrauh-Goebel F Lledo G Chibaudel B | 2007 | Proc Am Soc Clin Oncol2007，，18： | 1 |
| 6 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study显示文摘 | CHIBAUDEL B MAINDRAULT GOEBEL F LLEDO G | 2009 | J Clin Oncol2009，27，34： | 1 |
| 7 | StageⅡand stageⅢcolon cancer:treatment advances and future directions显示文摘 | Rousseau B Chibaudel B Bachet JB | 2010 | Cancer J2010，16，3： | 1 |
| 8 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer?The GERCOR OPTIMOX2 Study 显示文摘 | Chibaudel B Maindrault-Goebel F Lledo G | 2009 | J Clin Oncol2009，27，34： | 1 |
| 9 | FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer显示文摘AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the 'irinotecan-na?ve' patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the 'pre-exposed irinotecan' patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept. | CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol Christophe Borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel | 2018 | World Journal of Clinical Oncology2018，9，5： | 1 |
| 10 | Therapeutic strategy in unresectable metastatic colorectal cancer显示文摘 | Chibaudel B Tournigand C Andre T | 2012 | Ther Adv Med Oncol2012，4，2： | 1 |
| 11 | Therapeutic strategy in unresectable metastatic colorectal cancer显示文摘 | Chibaudel B Tournigand C André T | | 0，，02： | 1 |
| 12 | Therapeutic strategy in unresectable metastatic colorectal cancer 显示文摘 | Chibaudel B Tournigand C Andre T | 2012 | Ther Adv Med Oncol2012，4，2： | 1 |
| 13 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study 显示文摘 | Chibaudel B Maindrault-Goebel F Lledo G | 2009 | J Clin Oncol2009，27，34： | 1 |
| 14 | Can chemotherapy be discontinued in unresectable metastatic coloreetal cancer? The GERCOR OPTI- MOX2 Study显示文摘 | Chibaudel B Maindrault-Goebel F Lledo G | 2009 | J Clin Oncol2009，27，34： | 1 |
| 15 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study显示文摘 | Chibaudel B Maindrault-Goebel F Lledo G | 2009 | J Clin Oncol2009，27，： | 1 |
| 16 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study显示文摘 | CHIBAUDEL B MAINDRAULT-GOEBEL F LLEDO G | 2009 | J Clin Oncol2009，27，34： | 1 |
| 17 | Stage Ⅱ and stage Ⅲ colon cancer:treatment advances and future directions显示文摘 | Rousseau B Chibaudel B Bachet JB | 2010 | Cancer J2010，16，3： | 1 |
| 18 | FOLFIRI-3+ bevacizumab after the first-line in metastatic colorectal cancer显示文摘 | Bourges D Chibaudel B Bengrine-lefevre L | 2009 | Asco GI2009，417，： | 1 |
| 19 | Platinum-sensitivity in metastatic colorectal cancer: to- wards a definition显示文摘 | CHIBAUDEL B TOURNIGAND C BONNETAIN F | 2013 | Eur J Cancer2013，49，18： | 1 |
| 20 | Therapeutic strategy in unresectable metastatic colorectal cancer 显示文摘 | Chibaudel B Tournigand C Andr6 T | 2012 | T- her Adv Med Oneol2012，4，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员